A detailed history of State Of Wyoming transactions in Exelixis, Inc. stock. As of the latest transaction made, State Of Wyoming holds 2,702 shares of EXEL stock, worth $89,949. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,702
Previous 8,294 67.42%
Holding current value
$89,949
Previous $186,000 62.37%
% of portfolio
0.01%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$21.96 - $27.6 $122,800 - $154,339
-5,592 Reduced 67.42%
2,702 $70,000
Q2 2024

Aug 14, 2024

SELL
$20.34 - $23.73 $41,432 - $48,338
-2,037 Reduced 19.72%
8,294 $186,000
Q1 2024

May 13, 2024

BUY
$20.17 - $23.93 $73,277 - $86,937
3,633 Added 54.24%
10,331 $245,000
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $44,486 - $55,764
2,311 Added 52.68%
6,698 $160,000
Q3 2023

Nov 14, 2023

SELL
$19.04 - $22.74 $93,676 - $111,880
-4,920 Reduced 52.86%
4,387 $95,000
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $87,288 - $98,385
-4,804 Reduced 34.04%
9,307 $177,000
Q1 2023

May 12, 2023

SELL
$16.3 - $19.41 $180,343 - $214,752
-11,064 Reduced 43.95%
14,111 $273,000
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $251,283 - $292,099
16,797 Added 200.49%
25,175 $403,000
Q3 2022

Nov 14, 2022

BUY
$15.68 - $22.27 $37,349 - $53,047
2,382 Added 39.73%
8,378 $131,000
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $104,570 - $138,867
5,996 New
5,996 $125,000
Q1 2022

May 13, 2022

SELL
$17.03 - $22.67 $67,745 - $90,181
-3,978 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$15.84 - $21.88 $7,761 - $10,721
490 Added 14.05%
3,978 $73,000
Q3 2021

Feb 14, 2022

BUY
$16.3 - $21.14 $56,854 - $73,736
3,488 New
3,488 $74,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track State Of Wyoming Portfolio

Follow State Of Wyoming and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.